Ocular Therapeutix, Inc. (OCUL)
$3.18
Rating:
Recommendation:
Buy
| Symbol | OCUL |
|---|---|
| Price | $3.18 |
| Beta | 1.224 |
| Volume Avg. | 0.74M |
| Market Cap | 252.444M |
| Shares () | - |
| 52 Week Range | 2.57-7.96 |
| 1y Target Est | - |
| DCF Unlevered | OCUL DCF -> | |
|---|---|---|
| DCF Levered | OCUL LDCF -> | |
| ROE | -405.21% | Strong Sell |
| ROA | -78.03% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 2098.12% | Strong Buy |
| P/E | -2.79 | Sell |
| P/B | 80.40 | Strong Buy |
Latest OCUL news
About
Download (Excel)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.